Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011)

Diagnostic Microbiology and Infectious Disease

Volumn 76, Issue 2, 2013, Pages 217-221

  Sader, Helio S ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Carbapenem resistance; ESBL; KPC; MRSA; VRE

Indexed keywords

AMPICILLIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG POTENCY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER; ESCHERICHIA COLI; EUROPE; HUMAN; IN VITRO STUDY; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTH AMERICA; PHENOTYPE; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; ASIA; CEFTAZIDIME; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTER; ESCHERICHIA COLI; EUROPE; KLEBSIELLA; LATIN AMERICA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; NORTH AMERICA; QUALITY CONTROL; STENOTROPHOMONAS MALTOPHILIA; THIENAMYCINS;

EID: 84877830481     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.02.009     Document Type: Article

References (22)

1. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
2. Capone A., Giannella M., Fortini D., Giordano A., Meledandri M., Ballardini M., et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2012, 19:E23-E30.
3. Castanheira M., Sader H.S., Deshpande L.M., Fritsche T.R., Jones R.N. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008, 52:570-573.
4. Castanheira M., Sader H.S., Jones R.N. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb Drug Resist 2010, 16:61-65.
5. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition, (M07-A9) 2012, CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing: 22nd informational supplement, (M100-S22) 2012, CLSI, Wayne, PA.
7. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, January Available at, Accessed January 1, 2012. http://www.eucast.org/clinical_breakpoints/.
8. Farrell D.J., Turnidge J.D., Bell J., Sader H.S., Jones R.N. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect 2010, 60:440-451.
9. Fishbain J., Peleg A.Y. Treatment of Acinetobacter infections. Clin Infect Dis 2010, 51:79-84.
10. Gales A.C., Castanheira M., Jones R.N., Sader H.S. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012, 73:354-360.
11. IDSA The 10 X '20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010, 15:1081-1083.
12. Johnson A.P. Methicillin-resistant Staphylococcus aureus: the European landscape. J Antimicrob Chemother 2011, 66(Suppl 4):iv43-iv48.
13. Jones R.N., Ferraro M.J., Reller L.B., Schreckenberger P.C., Swenson J.M., Sader H.S. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007, 45:227-230.
14. Lode H.M. Clinical impact of antibiotic-resistant Gram-positive pathogens. Clin Microbiol Infect 2009, 15:212-217.
15. Mendes R.E., Farrell D.J., Sader H.S., Jones R.N. Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005-2009). Diagn Microbiol Infect Dis 2010, 68:307-311.
16. Mendes R.E., Sader H.S., Deshpande L., Jones R.N. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis 2008, 60:433-436.
17. Noskin G.A. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005, 41(Suppl 5):S303-S314.
18. Perez F., Endimiani A., Ray A.J., Decker B.K., Wallace C.J., Hujer K.M., et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: Impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010, 65:1807-1818.
19. Sader H.S., Farrell D.J., Jones R.N. Susceptibility of Klebsiella spp. to colistin and polymyxin B: Results from the SENTRY Antimicrobial Surveillance Program (2006-2009). Int J Antimicrob Agents 2011, 37:174-175.
20. Sader H.S., Farrell D.J., Jones R.N. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009). Diagn Microbiol Infect Dis 2011, 69:223-227.
21. Tygacil Package Insert Wyeth Pharmaceuticals, Philadelphia, PA Available at, Accessed September 2012. http://www.tygacil.com.
22. Werner G., Coque T.M., Hammerum A.M., Hope R., Hryniewicz W., Johnson A., et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 2008, 13:19046.